Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Front Immunol ; 10: 2501, 2019.
Article in English | MEDLINE | ID: mdl-31695703

ABSTRACT

Adoptive T cell therapy using patient T cells redirected to recognize tumor-specific antigens by expressing genetically engineered high-affinity T-cell receptors (TCRs) has therapeutic potential for melanoma and other solid tumors. Clinical trials implementing genetically modified TCRs in melanoma patients have raised concerns regarding off-target toxicities resulting in lethal destruction of healthy tissue, highlighting the urgency of assessing which off-target peptides can be recognized by a TCR. As a model system we used the clinically efficacious NY-ESO-1-specific TCR C259, which recognizes the peptide epitope SLLMWITQC presented by HLA-A*02:01. We investigated which amino acids at each position enable a TCR interaction by sequentially replacing every amino acid position outside of anchor positions 2 and 9 with all 19 possible alternative amino acids, resulting in 134 peptides (133 altered peptides plus epitope peptide). Each peptide was individually evaluated using three different in vitro assays: binding of the NY-ESOc259 TCR to the peptide, peptide-dependent activation of TCR-expressing cells, and killing of peptide-presenting target cells. To represent the TCR recognition kernel, we defined Position Weight Matrices (PWMs) for each assay by assigning normalized measurements to each of the 20 amino acids in each position. To predict potential off-target peptides, we applied a novel algorithm projecting the PWM-defined kernel into the human proteome, scoring NY-ESOc259 TCR recognition of 336,921 predicted human HLA-A*02:01 binding 9-mer peptides. Of the 12 peptides with high predicted score, we confirmed 7 (including NY-ESO-1 antigen SLLMWITQC) strongly activate human primary NY-ESOc259-expressing T cells. These off-target peptides include peptides with up to 7 amino acid changes (of 9 possible), which could not be predicted using the recognition motif as determined by alanine scans. Thus, this replacement scan assay determines the "TCR fingerprint" and, when coupled with the algorithm applied to the database of human 9-mer peptides binding to HLA-A*02:01, enables the identification of potential off-target antigens and the tissues where they are expressed. This platform enables both screening of multiple TCRs to identify the best candidate for clinical development and identification of TCR-specific cross-reactive peptide recognition and constitutes an improved methodology for the identification of potential off-target peptides presented on MHC class I molecules.


Subject(s)
Biological Assay , Epitopes, T-Lymphocyte/analysis , Lymphocyte Activation , Peptides/analysis , Receptors, Antigen/immunology , T-Lymphocytes/immunology , Cell Line, Tumor , Epitopes, T-Lymphocyte/chemistry , Epitopes, T-Lymphocyte/genetics , Epitopes, T-Lymphocyte/immunology , HEK293 Cells , Humans , Peptides/chemistry , Peptides/genetics , Peptides/immunology , Receptors, Antigen/genetics , T-Lymphocytes/cytology
2.
Anticancer Res ; 39(8): 4117-4128, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31366496

ABSTRACT

BACKGROUND/AIM: Carbonic anhydrase 12 (CA12) is a membrane-associated enzyme that is highly expressed on many human cancers. It is a poor prognostic marker and hence an attractive target for cancer therapy. This study aimed to develop a humanized CA12-antibody with anti-cancer activity. MATERIALS AND METHODS: Antibody libraries were constructed and screened by the Retrocyte display®. Antibody binding and blocking properties were determined by ELISA, flow cytometry and enzymatic activity assays. Spheroid viability was determined by Cell-Titer-Fluor assay. RESULTS: We developed a novel humanized CA12-specific antibody, 4AG4, which recognized CA12 as an antigen and blocked CA12 enzymatic activity. Our humanized CA12-antibody significantly inhibited spheroid growth of lung adenocarcinoma A549-cells in vitro by blocking CA12 enzymatic activity. Similar anti-tumor effects were recapitulated with CA12-gene knockout of A549-cells. CONCLUSION: Our newly identified humanized CA12-antibody with anti-cancer activity, represents a new tool for the treatment of CA12-positive tumors.


Subject(s)
Adenocarcinoma of Lung/drug therapy , Antibodies, Monoclonal, Humanized/pharmacology , Carbonic Anhydrases/genetics , A549 Cells , Adenocarcinoma of Lung/genetics , Adenocarcinoma of Lung/immunology , Adenocarcinoma of Lung/pathology , Antibodies, Monoclonal, Humanized/immunology , Carbonic Anhydrases/immunology , Cell Proliferation/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Spheroids, Cellular/drug effects
3.
J Enzyme Inhib Med Chem ; 30(6): 955-60, 2015 Dec.
Article in English | MEDLINE | ID: mdl-25775095

ABSTRACT

Carbonic anhydrase 9 (CA9) and carbonic anhydrase 12 (CA12) were proposed as potential targets for cancer therapy more than 20 years ago. However, to date, there are only very few antibodies that have been described to specifically target CA9 and CA12 and also block the enzymatic activity of their targets. One of the early stage bottlenecks in identifying CA9- and CA12-inhibiting antibodies has been the lack of a high-throughput screening system that would allow for rapid assessment of inhibition of the targeted carbon dioxide hydratase activity of carbonic anhydrases. In this study, we show that measuring the esterase activity of carbonic anhydrase offers a robust and inexpensive screening method for identifying antibody candidates that block both hydratase and esterase activities of carbonic anhydrase's. To our knowledge, this is the first implementation of a facile surrogate-screening assay to identify potential therapeutic antibodies that block the clinically relevant hydratase activity of carbonic anhydrases.


Subject(s)
Aconitate Hydratase/antagonists & inhibitors , Antibodies, Monoclonal/pharmacology , Antigens, Neoplasm/metabolism , Carbonic Anhydrases/metabolism , Enzyme Inhibitors/pharmacology , Esterases/metabolism , Acetazolamide/chemistry , Acetazolamide/pharmacology , Aconitate Hydratase/metabolism , Antibodies, Monoclonal/chemistry , Carbonic Anhydrase IX , Dose-Response Relationship, Drug , Enzyme Inhibitors/chemistry , Humans , Molecular Structure , Structure-Activity Relationship
4.
Methods ; 65(1): 57-67, 2014 Jan 01.
Article in English | MEDLINE | ID: mdl-24036249

ABSTRACT

Over the last nearly three decades in vitro display technologies have played an important role in the discovery and optimization of antibodies and other proteins for therapeutic applications. Here we describe the use of retroviral expression technology for the display of full-length IgG on B lineage cells in vitro with a hallmark of a tight and stable genotype to phenotype coupling. We describe the creation of a high-diversity (>1.0E09 different heavy- and light-chain combinations) cell displayed fully human antibody library from healthy donor-derived heavy- and light-chain gene libraries, and demonstrate the recovery of high affinity target-specific antibodies from this library by staining of cells with a labeled target antigen and their magnetic- and flow cytometry-based cell sorting. The present technology represents a further evolution in the discovery of full-length, fully human antibodies using mammalian display, and is termed Retrocyte Display® (Retroviral B lymphocyte Display).


Subject(s)
Antibodies, Monoclonal/biosynthesis , Retroviridae/genetics , Animals , Antibodies, Monoclonal/genetics , B-Lymphocytes/metabolism , Cryopreservation , Drug Evaluation, Preclinical , Flow Cytometry , Genetic Variation , Genetic Vectors , HEK293 Cells , Humans , Immunoglobulin Heavy Chains/biosynthesis , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Light Chains/biosynthesis , Immunoglobulin Light Chains/genetics , Immunomagnetic Separation , Peptide Library , Protein Binding
5.
Brief Funct Genomic Proteomic ; 4(1): 16-26, 2005 May.
Article in English | MEDLINE | ID: mdl-15975261

ABSTRACT

For most cancers, survival rates depend on the early detection of the disease. So far, no biomarkers exist to cope with this difficult task. New proteomic technologies have brought the hope of discovering novel early cancer-specific biomarkers in complex biological samples and/or of the setting up of new clinically relevant test systems. Novel mass spectrometry-(MS) based technologies in particular, such as surface-enhanced laser desorption/ionisation time of flight (SELDI-ToF-MS), have shown promising results in the recent literature. Here, proteomic profiles of control and disease states are compared to find biomarkers for diagnosis. This paper aims to address the authors' own work and that of other groups in clinical cancer proteomics based on SELDI-ToF-MS. Shortcomings and hopes for the future are discussed.


Subject(s)
Biomarkers, Tumor/chemistry , Neoplasms/metabolism , Proteomics/methods , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Enzyme-Linked Immunosorbent Assay , Humans , Neoplasms/diagnosis , Neoplasms/epidemiology , Protein Array Analysis/methods , Software
6.
J Proteome Res ; 4(2): 586-90, 2005.
Article in English | MEDLINE | ID: mdl-15822938

ABSTRACT

Gastric cancer mortality is second only to lung cancer, and its prognosis is dismal. Using surface-enhanced laser desorption/ionization-time-of-flight mass spectrometry, we previously identified a single best mass, which could separate gastric cancer from patients without cancer, with a sensitivity of 89.9% and a specificity of 90%. Using protein liquid chromatography systems with various chromatography media and MS/MS analysis, we were able to identify thrombin light chain A, a proteolytic fragment of prothrombin, as the single best mass for early detection of gastric cancer patients. These findings indicate that disturbances in the coagulation-system are early events in gastric cancer biology and that a decrease or loss of thrombin light chain A, which we termed negative serum protein profiling, may contribute to the diagnosis of cancer patients.


Subject(s)
Dyspepsia/diagnosis , Proteome , Stomach Neoplasms/diagnosis , Thrombin , Adult , Aged , Aged, 80 and over , Amino Acid Sequence , Diagnosis, Differential , Dyspepsia/metabolism , Female , Humans , Immunoprecipitation , Male , Middle Aged , Molecular Sequence Data , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Stomach Neoplasms/metabolism , Thrombin/chemistry
7.
Microbiology (Reading) ; 150(Pt 9): 3075-3087, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15347765

ABSTRACT

The Gram-positive actinobacterium Rhodococcus opacus 1CP is able to utilize several (chloro)aromatic compounds as sole carbon sources, and gene clusters for various catabolic enzymes and pathways have previously been identified. Pulsed-field gel electrophoresis indicates the occurrence of a 740 kb megaplasmid, designated p1CP. Linear topology and the presence of covalently bound proteins were shown by the unchanged electrophoretic mobility after S1 nuclease treatment and by the immobility of the native plasmid during non-denaturing agarose gel electrophoresis, respectively. Sequence comparisons of both termini revealed a perfect 13 bp terminal inverted repeat (TIR) as part of an imperfect 583/587 bp TIR, as well as two copies of the highly conserved centre (GCTXCGC) of a palindromic motif. An initial restriction analysis of p1CP was performed. By means of PCR and hybridization techniques, p1CP was screened for several genes encoding enzymes of (chloro)aromatic degradation. A single maleylacetate reductase gene macA, the clc gene cluster for 4-chloro-/3,5-dichlorocatechol degradation, and the clc2 gene cluster for 3-chlorocatechol degradation were found on p1CP whereas the cat and pca gene clusters for the catechol and the protocatechuate pathways, respectively, were not. Prolonged cultivation of the wild-type strain 1CP under non-selective conditions led to the isolation of the clc- and clc2-deficient mutants 1CP.01 and 1CP.02 harbouring the shortened plasmid variants p1CP.01 (500 kb) and p1CP.02 (400 kb).


Subject(s)
Catechols/metabolism , Genes, Bacterial , Plasmids , Rhodococcus/genetics , Rhodococcus/metabolism , DNA, Bacterial/chemistry , DNA, Bacterial/isolation & purification , Electrophoresis, Agar Gel , Hydroxybenzoates/metabolism , Molecular Sequence Data , Multigene Family , Mutation , Nucleic Acid Hybridization , Oxidoreductases Acting on CH-CH Group Donors/genetics , Physical Chromosome Mapping , Sequence Analysis, DNA , Sequence Deletion , Single-Strand Specific DNA and RNA Endonucleases/metabolism , Terminal Repeat Sequences
8.
Pathol Res Pract ; 200(2): 83-94, 2004.
Article in English | MEDLINE | ID: mdl-15237917

ABSTRACT

In this review article, we describe some of the studies that have been performed using the surface-enhanced laser desorption ionization (SELDI) time-of-flight mass spectrometry and ProteinChip technology over the past few years, and highlight both their findings as well as limitations. Proteomic applications, such as target or marker identification and target validation or toxicology, will be addressed. We will also provide an examination of SELDI technology and go into the question of where possible future research may lead us.


Subject(s)
Protein Array Analysis/methods , Proteins/analysis , Proteomics , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Biomarkers/analysis , Humans , Protein Array Analysis/instrumentation , Proteins/genetics
9.
Pathol Res Pract ; 200(2): 155-63, 2004.
Article in English | MEDLINE | ID: mdl-15237924

ABSTRACT

Standardized sample preparation procedures constitute a prerequisite for obtaining reliable and reproducible results in gene expression research in humans. In particular, in diseases such as pancreatic cancer and pancreatitis, isolating epithelial cells is an important step preceding such research. In pancreatic tissue, the high amount of RNAases is a further problem when it comes to obtaining high-quality RNA, and the presence of secreted proteases accelerates protein degradation. We developed a successful method that addresses these different problems. This method, which uses epithelial cell surface antibody Ber-Ep4, proteases, and RNAases inhibitors, leads to a significant enrichment (> 95% purity) of epithelial cells from fresh human tissue samples and allows for both proteomics (Western Blot, 2D PAGE) and transcriptomics studies (rtPCR, cDNA microarray). Compared with other cell purification procedures, this method is characterized by several advantages: a large quantity of cells available for downstream analysis, combined transcriptomics and proteomics studies using the same samples, better reproducibility of proteomics studies, and an acceptable yield (63%) for gene expression arrays studies. Moreover, a quality control protocol addressing the needs of the industry and the requirements of regulatory agencies is proposed.


Subject(s)
Pancreas/metabolism , Pancreatic Diseases/genetics , Pancreatic Diseases/metabolism , Proteomics , Specimen Handling/methods , Transcription, Genetic , Epithelial Cells/metabolism , Epithelial Cells/pathology , Humans , Oligonucleotide Array Sequence Analysis , Pancreas/pathology , Pancreatic Diseases/pathology , Quality Control , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Specimen Handling/standards
10.
Microbiology (Reading) ; 150(Pt 2): 463-472, 2004 Feb.
Article in English | MEDLINE | ID: mdl-14766925

ABSTRACT

A gene cluster containing a gene for maleylacetate reductase (EC 1.3.1.32) was cloned from Ralstonia eutropha 335(T) (DSM 531(T)), which is able to utilize 4-fluorobenzoate as sole carbon source. Sequencing of this gene cluster showed that the R. eutropha 335(T) maleylacetate reductase gene, macA, is part of a novel gene cluster, which is not related to the known maleylacetate-reductase-encoding gene clusters. It otherwise comprises a gene for a hypothetical membrane transport protein, macB, possibly co-transcribed with macA, and a presumed regulatory gene, macR, which is divergently transcribed from macBA. MacA was found to be most closely related to TftE, the maleylacetate reductase from Burkholderia cepacia AC1100 (62 % identical positions) and to a presumed maleylacetate reductase from a dinitrotoluene catabolic gene cluster from B. cepacia R34 (61 % identical positions). By expressing macA in Escherichia coli, it was confirmed that macA encodes a functional maleylacetate reductase. Purification of maleylacetate reductase from 4-fluorobenzoate-grown R. eutropha 335(T) cells allowed determination of the N-terminal sequence of the purified protein, which was shown to be identical to that predicted from the cloned macA gene, thus proving that the gene is, in fact, recruited for growth of R. eutropha 335(T) with this substrate.


Subject(s)
Benzoates/pharmacokinetics , Cupriavidus necator/genetics , Oxidoreductases Acting on CH-CH Group Donors/genetics , Amino Acid Sequence , Base Sequence , Cloning, Molecular , Conserved Sequence , Cupriavidus necator/classification , Cupriavidus necator/enzymology , Cupriavidus necator/growth & development , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Molecular Sequence Data , Multigene Family , Oxidoreductases Acting on CH-CH Group Donors/chemistry , Phylogeny , Plasmids , Restriction Mapping , Sequence Alignment , Sequence Homology, Amino Acid
11.
BMC Biochem ; 3: 22, 2002 Aug 07.
Article in English | MEDLINE | ID: mdl-12167173

ABSTRACT

BACKGROUND: SCF ubiquitin ligases share the core subunits cullin 1, SKP1, and HRT1/RBX1/ROC1, which associate with different F-box proteins. F-box proteins bind substrates following their phosphorylation upon stimulation of various signaling pathways. Ubiquitin-mediated destruction of the fission yeast cyclin-dependent kinase inhibitor Rum1p depends on two heterooligomerizing F-box proteins, Pop1p and Pop2p. Both proteins interact with the cullin Pcu1p when overexpressed, but it is unknown whether this reflects their co-assembly into bona fide SCF complexes. RESULTS: We have identified Psh1p and Pip1p, the fission yeast homologues of human SKP1 and HRT1/RBX1/ROC1, and show that both associate with Pop1p, Pop2p, and Pcu1p into a ~500 kDa SCFPop1p-Pop2p complex, which supports polyubiquitylation of Rum1p. Only the F-box of Pop1p is required for SCFPop1p-Pop2p function, while Pop2p seems to be attracted into the complex through binding to Pop1p. Since all SCFPop1p-Pop2p subunits, except for Pop1p, which is exclusively nuclear, localize to both the nucleus and the cytoplasm, the F-box of Pop2p may be critical for the assembly of cytoplasmic SCFPop2p complexes. In support of this notion, we demonstrate individual SCFPop1p and SCFPop2p complexes bearing ubiquitin ligase activity. CONCLUSION: Our data suggest that distinct homo- and heterooligomeric assemblies of Pop1p and Pop2p generate combinatorial diversity of SCFPop function in fission yeast. Whereas a heterooligomeric SCFPop1p-Pop2p complex mediates polyubiquitylation of Rum1p, homooligomeric SCFPop1p and SCFPop2p complexes may target unknown nuclear and cytoplasmic substrates.


Subject(s)
Peptide Synthases/physiology , Schizosaccharomyces pombe Proteins/physiology , Schizosaccharomyces/enzymology , Binding Sites , Cell Compartmentation , Macromolecular Substances , Mutation , Peptide Synthases/chemistry , Peptide Synthases/genetics , Protein Structure, Tertiary , Protein Subunits , SKP Cullin F-Box Protein Ligases , Schizosaccharomyces/metabolism , Schizosaccharomyces pombe Proteins/chemistry , Schizosaccharomyces pombe Proteins/genetics , Schizosaccharomyces pombe Proteins/metabolism , Ubiquitins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...